Schnieders Capital Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $276K | Sell |
5,751
-2,000
| -26% | -$85.9K | 0.04% | 209 |
|
|
2026
Q1 | $285K | Sell |
7,751
-3,182
| -29% | -$151K | 0.05% | 172 |
|
|
2025
Q4 | $556K | Sell |
10,933
-1,983
| -15% | -$101K | 0.09% | 116 |
|
|
2025
Q3 | $717K | Buy |
12,916
+310
| +2% | +$18.1K | 0.13% | 103 |
|
|
2025
Q2 | $870K | Sell |
12,606
-2,980
| -19% | -$203K | 0.15% | 92 |
|
|
2025
Q1 | $1.08M | Buy |
15,586
+202
| +1% | +$16.7K | 0.23% | 74 |
|
|
2024
Q4 | $1.32M | Sell |
15,384
-6,460
| -30% | -$699K | 0.26% | 64 |
|
|
2024
Q3 | $2.6M | Sell |
21,844
-340
| -2% | -$45.3K | 0.5% | 43 |
|
|
2024
Q2 | $3.17M | Sell |
22,184
-179
| -0.8% | -$23.7K | 0.64% | 37 |
|
|
2024
Q1 | $2.87M | Buy |
22,363
+865
| +4% | +$103K | 0.59% | 42 |
|
|
2023
Q4 | $2.22M | Buy |
21,498
+7,120
| +50% | +$704K | 0.49% | 46 |
|
|
2023
Q3 | $1.31M | Buy |
14,378
+2,240
| +18% | +$197K | 0.29% | 65 |
|
|
2023
Q2 | $982K | Buy |
12,138
+200
| +2% | +$16.3K | 0.21% | 83 |
|
|
2023
Q1 | $950K | Hold |
11,938
| – | – | 0.21% | 84 |
|
|
2022
Q4 | $808K | Hold |
11,938
| – | – | 0.19% | 88 |
|
|
2022
Q3 | $595K | Hold |
11,938
| – | – | 0.16% | 97 |
|
|
2022
Q2 | $665K | Hold |
11,938
| – | – | 0.2% | 97 |
|
|
2022
Q1 | $663K | Hold |
11,938
| – | – | 0.16% | 103 |
|
|
2021
Q4 | $669K | Hold |
11,938
| – | – | 0.16% | 100 |
|
|
2021
Q3 | $573K | Hold |
11,938
| – | – | 0.15% | 103 |
|
|
2021
Q2 | $500K | Buy |
11,938
+2,750
| +30% | +$107K | 0.14% | 115 |
|
|
2021
Q1 | $310K | Hold |
9,188
| – | – | 0.09% | 146 |
|
|
2020
Q4 | $321K | Hold |
9,188
| – | – | 0.11% | 137 |
|
|
2020
Q3 | $319K | Sell |
9,188
-900
| -9% | -$30K | 0.12% | 122 |
|
|
2020
Q2 | $330K | Buy |
10,088
+300
| +3% | +$9.57K | 0.13% | 115 |
|
|
2020
Q1 | $295K | Buy |
9,788
+600
| +7% | +$17.9K | 0.14% | 114 |
|
|
2019
Q4 | $266K | Sell |
9,188
-806
| -8% | -$22.3K | 0.1% | 148 |
|
|
2019
Q3 | $258K | Hold |
9,994
| – | – | 0.1% | 134 |
|
|
2019
Q2 | $255K | Sell |
9,994
-1,200
| -11% | -$29.7K | 0.1% | 139 |
|
|
2019
Q1 | $292K | Buy |
11,194
+1,200
| +12% | +$29.5K | 0.13% | 118 |
|
|
2018
Q4 | $230K | Hold |
9,994
| – | – | 0.11% | 121 |
|
|
2018
Q3 | $236K | Hold |
9,994
| – | – | 0.1% | 135 |
|
|
2018
Q2 | $230K | Sell |
9,994
-400
| -4% | -$9.51K | 0.1% | 138 |
|
|
2018
Q1 | $256K | Hold |
10,394
| – | – | 0.11% | 128 |
|
|
2017
Q4 | $279K | Hold |
10,394
| – | – | 0.12% | 132 |
|
|
2017
Q3 | $250K | Hold |
10,394
| – | – | 0.11% | 131 |
|
|
2017
Q2 | $223K | Buy |
+10,394
| New | +$210K | 0.1% | 141 |
|
Other funds holding NVO
F
Schnieders Capital Management's NVO Position: Q2 2026 in Review
Schnieders Capital Management reduced its Novo Nordisk (NVO) stake by 26% in Q2 2026, selling an estimated $85.9K and leaving 5,751 shares worth $276K. The position accounts for 0.04% of the portfolio, ranked #209.
Schnieders Capital Management first reported a position in NVO in Q2 2017 and has held it in 37 quarters since. The position peaked at $3.17M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Schnieders Capital Management held 5,751 shares of Novo Nordisk worth $276K as of Q2 2026.
- Schnieders Capital Management sold 2,000 Novo Nordisk shares in Q2 2026, an estimated $85.9K.
- Novo Nordisk made up 0.04% of Schnieders Capital Management's portfolio in Q2 2026, its #209 holding.
- Schnieders Capital Management first reported a position in Novo Nordisk in Q2 2017 and has held it in 37 quarters since.
- Schnieders Capital Management's Novo Nordisk position peaked at $3.17M in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Schnieders Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.